Background: Hypertensive disorders are the most common medical disorders in pregnancy contributing significantly to maternal and perinatal mortality and morbidity worldwide. The incidence is around 3-10% of all pregnancies. The aim of antihypertensives is to reduce, stabilize the blood pressure and thus minimize the risks such as placental abruption, maternal cardiac failure, cerebral hemorrhage; but they should not have any adverse effects on the uteroplacental circulation and the fetus. Antihypertensive drugs are often used to lower blood pressure to prevent this progression to adverse outcomes for the mother and the fetus. The risk of developing severe hypertension is reduced to half by using antihypertensive medications. The aim and objectives of the study was a comparative study of the efficacy of methyldopa, nifedipine versus labetalol and the feto-maternal outcome in gestational hypertension in a tertiary care referral centre. Methods: A prospective study on 240 outpatients as well as inpatients of the antenatal ward of Obstetrics and Gynaecology department of Chhattisgarh Institute of Medical Sciences, Bilaspur which is a tertiary care referral hospital. The patients randomly divided in three groups. The first group received alpha-methyl dopa 250mg tds, second 20 mg bd nifedipine and the third one labetalol 100mg bd. Mean arterial pressure calculated by systolic BP +2 DBP/3.The fall in BP calculated along with time required, dose of drug required, spontaneous/ induced labour or caesarean section, adverse maternal and the fetal outcome was observed. Results: Maximum number of patients that is 145(60.42%) patients belonged to the age group of 19 to 24 years and were primigravida (70.42%) presenting at 33-37 weeks of gestation. Significant fall in MAP was seen in patients receiving nifedipine and labetalol. Mean time to control blood pressure is 46.32 hrs in methyldopa group, 30.44hrs in nifedipine group and 37.24 hrs in labetalol group. 103 (42.9%) patients had normal delivery whereas 137 (57.1%) required a caesarian section, higher rate of spontaneous labour in nifedipine and labetalol group. Most common sideeffect observed was headache; the other side effects included drowsiness, more in patients treated with methyldopa, weakness, more in patients treated with labetalol. The fetal outcome was better with labetalol and nifedipine than methyl-dopa group. Conclusions: The decreased association from maternal and fetal side-effects, the comparatively better hypotensive action indicates that labetalol and nifedipine is suitable for use during pregnancy. Labetalol is safer, quicker in achieving adequate control of blood pressure with considerable prolongation of the duration of pregnancy with fewer side effects on the mother as well as the neonate when used in the management hypertensive disorders of pregnancy.

Background: Hypertensive disorders of pregnancy constitute one of the major threats to maternal health. Eclampsia is still a leading cause of maternal morbidity and mortality in developing countries. This study was carried out to determine the incidence of eclampsia, demographic profile of patients, obstetric outcome, fetal outcome, maternal morbidity and mortality. Methods: A 5 year retrospective observational study included 521 patients who presented in emergency with eclampsia and admitted between April 2010 and March 2015, in the department of Obstetrics and gynecology, government medical college (Chhattisgarh institute of medical sciences) and tertiary care hospital Bilaspur, Chhattisgarh. Results: Based on 14,876 pregnancies in the 5 year period in our referral hospital, we estimated an incidence of 3.5%.70.8% were primigravida and 86.4% of patients had no regular antenatal care. Majority of the cases (82.1%) presented as antepartum/intrapartum eclampsia in the age group 20-24 years (65.4%).The patients usually presented at term(62.4%) with 69.7% having vaginal delivery as compared to 30.3% undergoing LSCS. The fetal outcome showed 56.2% live-births, 25.5% had early neonatal death and 13.3% stillborn. The complications most commonly observed were puerperal sepsis (11 %),oliguria(8.1%), pulmonary edema(5.9%) and maternal mortality as 8.4 %. Conclusions: Most of the life-threatening eclampsia cases can be prevented by simple awareness and motivation towards antenatal care. In Chhattisgarh state where majority of rural population are tribal, illiterate, living in difficult to reach areas, delay in referral, due to unavailability of clinicians or medical officers in peripheral areas for antenatal examination.The best way to reduce the burden is by creating an awareness, proper antenatal care, timely referral and thus prevent the occurrence of eclampsia.

Background: Abnormal uterine bleeding (AUB) is defined as any alteration in the pattern or volume of menstrual blood flow. It is the common presenting complaint in gynecology out patient department (OPD) in all age groups. It is due to the anovulatory cycles which are commonly seen in extremes of age repro ductive age groups in adolescent and perimenopausal women. Abnormal uterine bleeding is caused by wide variety of organic or nonor ganic causes. Histopathological evaluation of the endo metrial samples plays a significant role in the diagnosis of abnormal uterine bleeding.

A fibroepithelial polyp (FEP) is a relatively uncommon benign condition of vulva, mainly of reactive origin, occurs in women of reproductive age, mostly during pregnancy. Here is a case which presented with bilateral vulval mass, for that she underwent surgical excision. Histopathological examination revealed bilateral fibroepithelial vulval polyp. After 4 years of uneventful interval same female came with term pregnancy with a huge vulval mass on left side, having similar characteristic features as previous one. Emergency cesarean section followed by excision of polyp in the same sitting done. Histopathological report confirmed the finding of fibroepithelial polyp this time also. Only few cases of recurrent fibroepithelial polyp of vulva associated with pregnancy have been reported till date. [Int J Reprod Contracept Obstet Gynecol 2013; 2(2.000): 245-247

Bacterial Vaginosis (BV) also called no-specific vaginitis develops when the normally predominant peroxide producing lactobacillus species in the vagina are replaced by mixed predominantly anaerobic flora consisting of Gardnerella vaginalis. Mycoplasma hominis, Mobiluncus species, Bacteroides species, Prevotela species, Peptostreptocococcus species, Fusobacterium species and Porphyromonas species. 1 Risk factors associated with developing Bacterial vaginosis are include intrauterine contraceptive device, multiple sexual partners, recent antibiotics use and passive cigarette smoking. Although sexual intercourse is thought to play a role in its transmission, Bacterial vaginosis is not considered exclusively sexually transmitted disease. Patients with bacterial vaginosis most commonly present with a foul (musty) fishy vaginal odour or a thin, white vaginal discharge. The diagnosis of bacterial vaginosis is determined if three of the following four sings (Ames's Criteria) are Present-1. Presence of clue cells. 2. Homogenous white, non-inflammatory discharge that adheres to the vaginal walls. 3. pH of vaginal fluid >4.5